<DOC>
	<DOCNO>NCT02372006</DOCNO>
	<brief_summary>Open-label , dose escalation , monotherapy , basket trial biomarker specific MTD expansion cohort The trial consist 2 part : 1 . Dose find part determine MTD 2 . Biomarker specific MTD expansion cohort assess clinical anti-tumour activity include tumour type</brief_summary>
	<brief_title>Phase I Trial Afatinib Pediatric Tumours</brief_title>
	<detailed_description />
	<mesh_term>Neuroectodermal Tumors</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive</mesh_term>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<criteria>Inclusion criterion : Paediatric patient age 2 year &lt; 18 year time inform consent diagnosis HGG , DIPG , low grade astrocytoma , medulloblastoma/PNET , ependymoma , neuroblastoma , RMS tumours ErbB deregulation recurrent/refractory disease receive least one prior standard treatment regimen effective conventional therapy exist Performance status &gt; = 50 % ( Lansky = &lt; 12ys ; Karnofsky &gt; 12ys ) Exclusion criterion : relevant toxicity previous treatment know preexist relevant cardiac , hepatic , renal , bone marrow dysfunction , ILD , keratitis</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>